Latest on Pharmaceutical Industry


Ablynx signs Sanofi deal potentially worth up to $2.8 billion

French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion). Initial payments a..Read More...

Neuland Laboratories Unveils Dedicated Process Engineering Lab

Neuland Laboratories Limited, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in about 80 countries..Read More...



6th European Trial Master File Summit

London Marriott Hotel Regents Park,
United Kingdom,
ExL Events

Press Releases

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

Churchill Pharmaceuticals LLC a privately held company devoted to expanding treatment options with oral oncology agents announces that the New Drug Application NDA for YONSA abiraterone acetate ultramicrosize tablets has.. Read More...

FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis

Novartis today announced that the US Food and Drug Administration FDA has accepted for review the Biologics License Application BLA for AMG 334 erenumab for the prevention of migraine in patients experiencing four or mor.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics